

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 64117

**Title:** Infliximab treatment of glycogenosis Ib with Crohn's -like enterocolitis: A case report

**Reviewer's code:** 01562153

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Doctor, Professor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-09

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-02-10 03:49

**Reviewer performed review:** 2021-02-10 17:44

**Review time:** 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
<https://www.wjgnet.com>

## **SPECIFIC COMMENTS TO AUTHORS**

In this manuscript, the authors presented a 13-year-old boy who was diagnosed as glycogen storage disease type Ib with Crohn's disease-like colitis. The patient was treated with granulocyte colony-stimulating factor (G-CSF), but the symptoms did not improve significantly. So infliximab was administered. After 6 months of treatment (5th infliximab treatment), the disease activity index and all the inflammatory indexes decreased, and a review of the colonoscopy data showed that the ulcers were smoothened. This is an interesting study case of glycogen storage disease type Ib with Crohn's disease-like colitis. Usually, the symptoms of intestinal inflammation in glycogen storage disease type Ib can be alleviated by G-CSF treatment. The G-CSF treatment was failed in this patient. The authors tried infliximab and obtained an excellent response. This article can provide useful information for the clinicians to manage the intestinal inflammation in patients with glycogen storage disease type Ib.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 64117

**Title:** Infliximab treatment of glycogenosis Ib with Crohn's -like enterocolitis: A case report

**Reviewer's code:** 05227913

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-09

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-02-10 06:56

**Reviewer performed review:** 2021-02-16 19:15

**Review time:** 6 Days and 12 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

I think that a detailed and carefully written article will contribute to the literature. Congratulations on your successful treatment. Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab, improve survival in several cancer types. The fact that Infliximab can also be used in the treatment of enterocolitis will positively affect the treatment process in this difficult disease.